The forecast for the re-import of antisera and other blood fractions to Italy indicates a steady increase from 2024 to 2028, starting at $96.685 million and reaching $110.13 million. The year-on-year growth fluctuates between approximately 3.5% to 3.3%, demonstrating consistent market growth. The compounded annual growth rate (CAGR) over the forecast period is expected to be around 3.3%, highlighting a stable trajectory. In 2023, this figure stood below $96.685 million, marking a consistent upward trend since then.
Future trends to observe include:
- The impact of technological advancements in blood fractionation techniques.
- Changing regulatory environments in Italy and the EU.
- Emerging competition from synthetic alternatives in the pharmaceutical space.
